The compartmentalized nature of FXR signaling underscores the importance of developing tissue-targeted FXR modulators for metabolic disorders, as systemic FXR activation or inhibition may produce conflicting physiological effects due to the receptor’s distinct regulatory roles in different organ systems. This evidence concerns the gene NR1H4 and metabolic disease.